Rapport Therapeutics Inc.
RAPP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.36B
Close$
$0.88
97.7% downside
Current Fair Value
97.7% downsideOvervalued by 97.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.36 Billion |
|---|---|
| Enterprise Value | $1.30 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.86 |
| Beta | 0.98 |
| Outstanding Shares | 47,236,618 |
Return
| Return on Equity | -22.75% |
|---|---|
| Return on Assets | -21.56% |
| Return on Invested Capital | -26.11% |
Valuation & Multiples
| P/E Ratio | -16.44 |
|---|---|
| PEG | 94.06 |
| Price to Sales | - |
| Price to Book Ratio | 4.32 |
| Enterprise Value to Revenue | 64.78 |
| Enterprise Value to EBIT | -10.34 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
$7.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
$2.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5676▼ 8.24% |
|---|---|
| Total Calls | 18,500▼ 28.85% |
| Total Puts | 10,500▼ 37.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 111.72%▼ 22.96% |
|---|---|
| Total Invested | $1.64B▲ 5.91% |
| Investors Holding | 148▲ 2.00% |
ESG Score
No data